ACADIA Pharmaceuticals Inc. (ACAD)

16.87
NASDAQ : Health Technology
Prev Close 16.87
Day Low/High 0.00 / 0.00
52 Wk Low/High 14.51 / 41.20
Avg Volume 3.15M
Exchange NASDAQ
Shares Outstanding 124.83M
Market Cap 2.18B
EPS -2.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

NUPLAZID® (pimavanserin) Bottle (Photo: Business Wire)

NUPLAZID® (pimavanserin) Bottle (Photo: Business Wire)

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced FDA approval of a new capsule dose formulation and a new tablet strength of NUPLAZID (pimavanserin) to help in the treatment of patients living with hallucinations and delusions associated with...

ACADIA Pharmaceuticals To Present At The JMP Securities Life Sciences Conference On June 20, 2018

ACADIA Pharmaceuticals To Present At The JMP Securities Life Sciences Conference On June 20, 2018

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at...

ACADIA Pharmaceuticals To Present At The Goldman Sachs 39th Annual Global Healthcare Conference On June 13, 2018

ACADIA Pharmaceuticals To Present At The Goldman Sachs 39th Annual Global Healthcare Conference On June 13, 2018

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at...

3 Biotech Best Bets From the 'Stock Picker of the Year'

3 Biotech Best Bets From the 'Stock Picker of the Year'

In 2017, McCamant's model portfolio rose 65%, while his trader's portfolio rose 98%.

First Week Of July 20th Options Trading For Acadia Pharmaceuticals (ACAD)

Investors in Acadia Pharmaceuticals Inc saw new options begin trading this week, for the July 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new July 20th contracts and identified one put and one call contract of particular interest.

ACADIA Pharmaceuticals To Present At The Bank Of America Merrill Lynch Health Care Conference 2018

ACADIA Pharmaceuticals To Present At The Bank Of America Merrill Lynch Health Care Conference 2018

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at...

ACADIA Pharmaceuticals Reports First Quarter 2018 Financial Results

ACADIA Pharmaceuticals Reports First Quarter 2018 Financial Results

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced its financial...

Elena Ridloff, CFA, Senior Vice President, Investor Relations (Photo: Business Wire)

Elena Ridloff, CFA, Senior Vice President, Investor Relations (Photo: Business Wire)

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced that Elena Ridloff,...

ACADIA Pharmaceuticals To Announce First Quarter 2018 Financial Results On May 4, 2018

ACADIA Pharmaceuticals To Announce First Quarter 2018 Financial Results On May 4, 2018

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will report its...

ACADIA Pharmaceuticals Announces Presentation Of Clinical Experience Data For NUPLAZID (Pimavanserin) At 2018 American Academy Of Neurology (AAN) Annual Meeting

ACADIA Pharmaceuticals Announces Presentation Of Clinical Experience Data For NUPLAZID (Pimavanserin) At 2018 American Academy Of Neurology (AAN) Annual Meeting

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced poster presentations...

ACADIA Pharmaceuticals Issues Statement Reaffirming Benefit/Risk Profile Of NUPLAZID

ACADIA Pharmaceuticals Issues Statement Reaffirming Benefit/Risk Profile Of NUPLAZID

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today issued the following statement: NUPLAZID ® (pimavanserin) is the only medicine approved in the United States to treat hallucinations and delusions associated with Parkinson's disease psychosis.

June 8th Options Now Available For Acadia Pharmaceuticals (ACAD)

Investors in Acadia Pharmaceuticals Inc saw new options become available today, for the June 8th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ACAD options chain for the new June 8th contracts and identified the following call contract of particular interest.

PMDAlliance And ACADIA Pharmaceuticals Survey Reveals Serious Quality-of-Life Impact Of Non-Movement Symptoms Of Parkinson's Disease

PMDAlliance And ACADIA Pharmaceuticals Survey Reveals Serious Quality-of-Life Impact Of Non-Movement Symptoms Of Parkinson's Disease

As part of Parkinson's Disease Awareness Month, the Parkinson & Movement Disorder Alliance (PMDAlliance) and ACADIA Pharmaceuticals Inc.

Lennar, LG Homes, GrubHub, Sprint: 'Mad Money' Lightning Round

Lennar, LG Homes, GrubHub, Sprint: 'Mad Money' Lightning Round

Jim Cramer looks at Lennar, LG Homes, GrubHub, Sprint, Acadia Pharmaceuticals, Pilgrim's Pride, Opko Health and more.

A Flash Flood of Selling: Cramer's 'Mad Money' Recap (Thursday 4/19/18)

A Flash Flood of Selling: Cramer's 'Mad Money' Recap (Thursday 4/19/18)

Interest rates, inflation and bonds all add up, says Jim Cramer. And now, the trade war with China's getting ugly.

ACADIA Pharmaceuticals To Present At The 17th Annual Needham Healthcare Conference On March 27, 2018

ACADIA Pharmaceuticals To Present At The 17th Annual Needham Healthcare Conference On March 27, 2018

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

Acadia Pharmaceuticals Stock Sees Short Interest Move 10.7% Lower

Acadia Pharmaceuticals Stock Sees Short Interest Move 10.7% Lower

The most recent short interest data has been released for the 02/28/2018 settlement date, which shows a 1,239,260 share decrease in total short interest for Acadia Pharmaceuticals Inc , to 10,355,126, a decrease of 10.69% since 02/15/2018. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

3 Good Bargain Stocks With Insider Buying

3 Good Bargain Stocks With Insider Buying

I continue to keep a 'shopping list' at the ready for the next dip in the market.

ACADIA Pharmaceuticals To Present At The Cowen And Company 38th Annual Health Care Conference On March 13, 2018

ACADIA Pharmaceuticals To Present At The Cowen And Company 38th Annual Health Care Conference On March 13, 2018

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

ACADIA Pharmaceuticals Reports Fourth Quarter And Full Year 2017 Financial Results

ACADIA Pharmaceuticals Reports Fourth Quarter And Full Year 2017 Financial Results

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders,...

ACADIA Pharmaceuticals To Announce Fourth Quarter And Full Year 2017 Financial Results On February 27, 2018

ACADIA Pharmaceuticals To Announce Fourth Quarter And Full Year 2017 Financial Results On February 27, 2018

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

These 2 Biotech Stocks Still Have Upside

These 2 Biotech Stocks Still Have Upside

The biotech sector has seen a big rally, but there are still opportunities.

ACADIA Pharmaceuticals To Present At The 36th Annual J.P. Morgan Healthcare Conference On January 9, 2018

ACADIA Pharmaceuticals To Present At The 36th Annual J.P. Morgan Healthcare Conference On January 9, 2018

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

January Setting Up to Be a Volatile Month

Sentiment readings are at extreme levels with the chance for overbought conditions heading into the New Year.

Damien McDevitt, Ph.D., Senior Vice President, Corporate Development (Photo: Business Wire)

Damien McDevitt, Ph.D., Senior Vice President, Corporate Development (Photo: Business Wire)

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders,...

What's Holding Up This Market?: Cramer's 'Mad Money' Recap (Monday 12/11/17)

What's Holding Up This Market?: Cramer's 'Mad Money' Recap (Monday 12/11/17)

It's just very hard to keep stocks down in this environment, says Jim Cramer. It's part of a synchronized global expansion.

ACADIA Pharmaceuticals To Present At The 29th Annual Piper Jaffray Healthcare Conference On November 28, 2017

ACADIA Pharmaceuticals To Present At The 29th Annual Piper Jaffray Healthcare Conference On November 28, 2017

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today...

TheStreet Quant Rating: D- (Sell)